GET DAILY SIGNALSNiagen Bioscience (NAGE) Faces Q3 Headwinds: What the -20% Sales Drop Means
Key Takeaways
- Third quarter 2026 net sales came in at $27.2 million, down 20% year over year and below the consensus estimate of roughly $31.9 million.
- Niagen Bioscience posted a net loss of $1.2 million, or $0.01 per diluted share, versus net income of $4.6 million, or $0.06 per diluted share, in the year-ago quarter.
- Adjusted EBITDA stayed positive at about $0.5 million, and the company generated roughly $2.6 million in operating cash flow.
- Tru Niagen revenue declined 10% year over year to $23.3 million, while the Niagen Ingredients business contributed $3.8 million.
- The company ended the quarter with $69.5 million in cash, a debt-free balance sheet, and $83.3 million in working capital.
- For full-year 2026, management reiterated expectations for direct website revenue growth of 15% to 20% and overall e-commerce growth of approximately 5%.
Earnings Context and Why It Matters
Niagen Bioscience is a healthy-aging company built around NAD+ (nicotinamide adenine dinucleotide), a coenzyme that declines with age, and its flagship ingredient Niagen, a patented form of nicotinamide riboside. The third quarter of 2026 tested whether the company can sustain its growth narrative while navigating near-term commercial headwinds. After a strong fiscal 2025 and double-digit revenue expansion in recent years, I was watching closely to see whether softer consumer demand and spending on new initiatives would pressure the top line. Because NAGE operates across consumer products, ingredients, and pharmaceutical channels, this report also offers a read on the broader healthy-aging and supplement market, making it a meaningful checkpoint for both growth-focused and value-oriented investors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Niagen Bioscience reported net sales of $27.2 million, a 20% decline from $34.0 million in the same period last year and below the consensus estimate of about $31.9 million. The company recorded a net loss of $1.2 million, or $0.01 per diluted share, compared with net income of $4.6 million, or $0.06 per diluted share, a year earlier, missing the consensus estimate of breakeven results.
Within revenue, Tru Niagen contributed $23.3 million, down 10% year over year, while the Niagen Ingredients segment generated $3.8 million, including $3.4 million of food-grade Niagen and $425,000 of pharmaceutical-grade Niagen. Despite the top-line decline, the company maintained positive adjusted EBITDA of approximately $0.5 million and generated about $2.6 million in operating cash flow during the quarter. Niagen Bioscience ended the period with $69.5 million in cash, no debt, and $83.3 million in working capital.
Management also reiterated full-year 2026 expectations for direct website revenues to grow 15% to 20% and for overall e-commerce to grow approximately 5% year over year. From what I see, the cash position remains a key strength here.
Market Reaction and Investor Sentiment
NAGE shares fell in after-hours trading on November 4, 2026, after the results were released, reflecting investor disappointment over the revenue miss and the swing to a net loss. The roughly 9% after-hours decline suggested that the market had anticipated a steadier performance, particularly given the company's history of top-line growth. Sentiment around the stock has been under pressure for much of 2026, with the share price trading well below its 52-week high and a substantial portion of the float held short. Against that backdrop, the softer Tru Niagen results and elevated spending on brand, retail, and research initiatives weighed on confidence, even as the company's cash position and debt-free balance sheet offered a measure of stability.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether Niagen Bioscience can convert its reiterated full-year guidance into actual revenue improvement. The company expects direct website revenue to grow 15% to 20% in 2026, which makes the fourth quarter a critical test of demand recovery in its core e-commerce channel.
Several initiatives could shape the trajectory from here. The company is expanding pharmaceutical-grade Niagen through Niagen Plus and advancing its skincare portfolio, including the early launch of Niagen NanoCloud, which management described as generating strong early sales. A recently launched brand campaign and broader retail distribution may also support the consumer business, though increased selling and marketing expenses are expected to continue.
Cost trends will remain in focus, as the company anticipates higher research and development and general and administrative spending to support its pipeline, including the preclinical and IND-enabling development of NB4168. Management also noted that litigation-related expenses were elevated during the quarter and could ease once those matters are resolved.
Finally, the strength of the balance sheet, with $69.5 million in cash and no debt, provides flexibility as the company funds these growth initiatives. Investors will likely monitor whether operating cash flow remains positive, whether ingredient and pharmaceutical revenue accelerate, and whether the consumer segment stabilizes heading into the holiday quarter.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating companies like this one, as it helps me quickly filter for technical patterns, fundamentals, and performance metrics across the sector. The tool has become a regular part of my workflow for spotting comparable names and refining ideas before digging deeper into earnings reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NAGE in -8.27% downward trend, sliding for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NAGE declined for three days, in 233 of 280 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for NAGE entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NAGE's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 72 cases where NAGE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on NAGE as a result. In 72 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for NAGE just turned positive on October 27, 2026. Looking at past instances where NAGE's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAGE advanced for three days, in 188 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
NAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.416) is normal, around the industry mean (5.975). P/E Ratio (12.600) is within average values for comparable stocks, (7.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (1.976) is also within normal values, averaging (5.003).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. NAGE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary-based ingredient technologies
Industry FoodMajorDiversified
Advertisement